ABSTRACT
El riesgo asociado de desarrollar una enfermedad linfoproliferativa en la enfermedad inflamatoria intestinal (EII) es un tema controvertido desde hace décadas y se discute si el riesgo se asocia a la inflamación crónica de la EII per se o a los tratamientos de la misma, especialmente los fármacos tiopurínicos (azatioprina y mercaptopurina) y los agentes anti-TNF-alfa. Presentamos un caso excepcional de un varón de 35 años diagnosticado de enfermedad de Crohn con 17 años y en tratamiento con azatioprina, que presentó años después, un linfoma de Hodgkin intestinal
The risk of developing a lymphoproliferative disease associated with inflammatory bowel disease (IBD) has been a controversial issue for decades; it is debatable whether the risk is associated with the chronic inflammation of IBD per se or its treatment, especially with thiopurine drugs (azathioprine and mercaptopurine) and anti-TNF-alfa agents. We present an unusual case of a 35-year-old man who had been diagnosed with Crohn's disease at age 17 and treated with azathioprine, presenting years later with an intestinal Hodgkin's lymphoma
Subject(s)
Humans , Male , Adult , Hodgkin Disease/drug therapy , Inflammatory Bowel Diseases/complications , Crohn Disease/pathology , Mercaptopurine/therapeutic use , Azathioprine/therapeutic use , Intestinal Neoplasms/pathology , Hodgkin Disease/pathology , Lymphoproliferative Disorders/epidemiology , Tumor Necrosis Factor-alpha/antagonists & inhibitorsABSTRACT
The risk of developing a lymphoproliferative disease associated with inflammatory bowel disease (IBD) has been a controversial issue for decades; it is debatable whether the risk is associated with the chronic inflammation of IBD per se or its treatment, especially with thiopurine drugs (azathioprine and mercaptopurine) and anti-TNF-α agents. We present an unusual case of a 35-year-old man who had been diagnosed with Crohn's disease at age 17 and treated with azathioprine, presenting years later with an intestinal Hodgkin's lymphoma.
